Consistently, in the primary tumour, the triple therapy group (IL-2/14d) showed a markedly increased percentage of CD3+ cell number and CD3+ cell density, along with greater CD3+ distance from the tumour border and thus depth of infiltration (Figure 6b. This evidence concerns the gene IL2 and neoplasm.